Description
Activation of the classical, alternate, or lectin complement pathways can result in the production of the C3a anaphylatoxin. C3a has been shown to be a multifunctional proinflammatory mediator. Thus, C3a has been shown to increase vascular permeability, to be spasmogenic and chemotactic, and to induce the release of pharmacologically active mediators from a number of cell types. C3a production in vivo may also initiate, contribute to, or exacerbate the inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ARDS, ischemic heart disease, post-dialysis syndrome, and several autoimmune diseases including rheumatoid arthritis, lupus erythematosus, and acute glomerulonephritis. In blood plasma or serum, once formed, the nascent C3a anaphylatoxin is rapidly cleaved to the C3a-desArg form by the endogenous serum carboxypeptidase N enzyme. Thus, the quantitation of C3a-desArg in plasma or experimental samples should yield a reliable measurement of the level of complement activation that has occurred in the test samples under investigation. The BD OptEIATM Human C3a ELISA Kit is for the in vitro quantitative determination of Human C3a-desArg in human EDTA plasma, serum and other biological samples.
Preparation And Storage
1. Store unopened kit at 2 - 8°C. Do not use kit after expiration date.
2. Before use, bring all reagents to room temperature (18 - 25°C). Immediately after use, return to proper storage conditions.
3. Lyophilized standards are stable until kit expiration date. After reconstitution, use freshly reconstituted standard within 12 hours (stored at 2 - 8°C).
| Description | Quantity/Size | Part Number | EntrezGene ID |
|---|---|---|---|
| Antibody Coated Wells | N/A | 51-27111E | N/A |
| Detection Antibody | N/A | 51-27112E | N/A |
| Standards | N/A | 51-27116E | N/A |
| Enzyme Concentrate Streptavidin-HRP | N/A | 51-9002833 | N/A |
| Standard/Sample Diluent | N/A | 51-2708KD | N/A |
| ELISA Diluent | N/A | 51-2707KD | N/A |
| Wash Concentrate (20X) | 100 mL (1 ea) | 51-9003738 | N/A |
| TMB One-Step Substrate Reagent | N/A | 51-2709KD | N/A |
| Stop Solution | N/A | 51-2608KC | N/A |
Development References (5)
-
Bokisch, VA, and HJ Muller-Eberhard. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970; 49:2427-36. (Biology).
-
Ember JA., Jagels MA., Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: J.E. Volanakis and M.M. Frank, ed. The human complement system in health and disease. Marcel Dekker, Inc; 1998:241-284.
-
Hugli, TE, and HJ Muller-Eberhard. Anaphylatoxins: C3a and C3a. Advances in Immunology. 1978; 26:1-53. (Biology).
-
Matsushita, M and T Fujita. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992; 176:1497-1502. (Biology).
-
Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem. 1999; 45(8):1190-1199. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
